P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1
Primaquine five days probably leads to higher P. vivax parasitaemia detected > 30 days after starting primaquine compared with 14 days (moderate certainty).
1 finding from 1 review
P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1
Primaquine three days probably leads to higher P. vivax parasitaemia detected > 30 days after starting primaquine compared with 14 days (moderate certainty).
1 finding from 1 review
P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1
Primaquine seven days may leads to higher P. vivax parasitaemia detected > 30 days after starting primaquine compared with 14 days (low certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (low certainty).
1 finding from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg showed no clear difference in participants with gametocytes at day 3 to 4 by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Clinical resolution · acute infectious diarrhoea in children
Smectite may leads to higher clinical resolution at day 3 compared with control (low certainty).
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
Severe adverse events · People with P. vivax malaria1
1 finding from 1 review
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
All‐cause mortality – at 28 to 30 days, or in‐hospital · people with confirmed COVID‐19
It is very uncertain whether favipiravir changes all‐cause mortality – at 28 to 30 days, or in‐hospital compared with no treatment, supportive treatment, or other antiviral treatment (very low certainty).
1 finding from 1 review
Time in hospital(days) · children with severe dehydration due to diarrhoea
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
All‐cause mortality at day 28 · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention may leads to lower all‐cause mortality at day 28 (low certainty).
1 finding from 1 review
Intervention not reported
Viral clearance at 14 days · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found